{
    "id": "35d3c939-2305-3f43-e063-6394a90afb4e",
    "indications": {
        "text": "guanfacine extended-release tablets indicated treatment attention deficit hyperactivity disorder ( adhd ) monotherapy adjunctive therapy stimulant medications [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "attention deficit hyperactivity disorder (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 recommended dose : 1 mg 7 mg ( 0.05 0.12 mg/kg target weight based dose range ) daily morning evening based response tolerability ( 2.2 ) . \u2022 begin dose 1 mg daily adjust increments 1 mg/week ( 2.2 ) . \u2022 crush , chew break tablets swallowing ( 2.1 ) . \u2022 administer high-fat meals , increased exposure ( 2.1 ) . \u2022 substitute immediate-release guanfacine tablets mg-per-mg basis , differing pharmacokinetic profiles ( 2.3 ) . \u2022 switching immediate-release guanfacine , discontinue treatment titrate guanfacine extended-release tablet directed ( 2.3 ) . \u2022 discontinuing , taper dose decrements 1 mg every 3 7 days avoid rebound hypertension ( 2.5 ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "guanfacine extended-release tablets usp , 1 mg white white colored , round shaped tablets , debossed \u2018 l657 \u2019 one side plain side . ndc 60760-863-30 bottles 30 storage- store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "guanfacine contraindicated patients history hypersensitivity reaction guanfacine extended-release tablets inactive ingredients , products containing guanfacine . rash pruritus reported .",
    "ingredients": [
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18012"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "GUANFACINE HYDROCHLORIDE",
            "code": "PML56A160O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5559"
        }
    ],
    "organization": "ST. MARY'S MEDICAL PARK PHARMACY",
    "name": "GUANFACINE",
    "effectiveTime": "20250523",
    "indications_original": "Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications\n \n  [see Clinical Studies (14)].",
    "contraindications_original": "\u2022\u00a0Recommended dose: 1 mg to 7 mg (0.05 to 0.12 mg/kg target weight based dose range) once daily in the morning or evening based on clinical response and tolerability (2.2). \u2022\u00a0Begin at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week (2.2). \u2022\u00a0Do not crush, chew or break tablets before swallowing (2.1). \u2022\u00a0Do not administer with high-fat meals, because of increased exposure (2.1). \u2022\u00a0Do not substitute for immediate-release guanfacine tablets on a mg-per-mg basis, because of differing pharmacokinetic profiles (2.3). \u2022\u00a0If switching from immediate-release guanfacine, discontinue that treatment and titrate with guanfacine extended-release tablet as directed (2.3). \u2022\u00a0When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days to avoid rebound hypertension (2.5).",
    "warningsAndPrecautions_original": "Guanfacine extended-release tablets USP, 1 mg are white to off white colored, round shaped tablets, debossed with \u2018L657\u2019 on one side and plain on other side.\n                  \n                  NDC 60760-863-30 BOTTLES OF 30\n                  \n                  \n                     Storage- Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Guanfacine is contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets\u00a0or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported.",
    "drug": [
        {
            "name": "GUANFACINE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5558"
        }
    ]
}